Grant: Collaborative Research and Development Grants
McMaster University
$126,200.00
Development of a patient-specific predictive tool and a regulatory testing machine for transcatheter heart valve replacement
EF 2019-20
Résumé
Cardiovascular disease is the leading cause of death globally and claims more lives than all forms of cancer combined. In Canada, one in every four deaths is from cardiovascular disease. It is the leading cause of burden on healthcare costing the Canadian economy more than $22 billion every year. Valvular disease is one of the most serious cardiovascular problems. Until recently, high-risk patients with valvular disease had no other option than the surgical aortic valve replacement procedure, which has a high mortality rate. Transcatheter valve replacement (TVR) is an emerging minimally invasive device. While many patients experience a significant improvement after TVR intervention, for others the situation worsens significantly. Therefore, there is a crucial need for a predictive tool which has the capability of evaluating TVR intervention scenarios in each patient before the actual intervention to avoid irreversible consequences. Such tool would predict effectiveness of interventions, allowing systematic testing of possible clinical solutions, and thus enable personalization of interventions. Moreover, manufacturers of TVR (and other artificial valves) must validate the design and durability of their devices before releasing them to the market. Despite its importance, there exists no realistic regulatory TVR testing machine. To address these needs, we will develop a platform to be used for two objectives: 1. As a predictive tool for planning clinical interventions: The tool will have the capability testing of effects of TVR intervention scenarios for correcting valvular diseases on the body of each patient body in a patient-specific manner. 2. As a regulatory medical-device testing machine: This machine can serve testing needs of medical-device companies by making it possible to perform many important in vivo evaluation routines in vitro and will significantly reduce the need for animal studies and human trials so it can significantly speed up the device approval process and reduce the time-to-market and cost-to-market for new devices.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
537352-2018
Name nom
KeshavarzMotamed, Zahra
Department département
Mechanical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2018
Award amount
126200
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Development of a patient-specific predictive tool and a regulatory testing machine for transcatheter heart valve replacement
Keyword
NSERC
Application summary
Cardiovascular disease is the leading cause of death globally and claims more lives than all forms of cancer combined. In Canada, one in every four deaths is from cardiovascular disease. It is the leading cause of burden on healthcare costing the Canadian economy more than $22 billion every year. Valvular disease is one of the most serious cardiovascular problems. Until recently, high-risk patients with valvular disease had no other option than the surgical aortic valve replacement procedure, which has a high mortality rate. Transcatheter valve replacement (TVR) is an emerging minimally invasive device. While many patients experience a significant improvement after TVR intervention, for others the situation worsens significantly. Therefore, there is a crucial need for a predictive tool which has the capability of evaluating TVR intervention scenarios in each patient before the actual intervention to avoid irreversible consequences. Such tool would predict effectiveness of interventions, allowing systematic testing of possible clinical solutions, and thus enable personalization of interventions. Moreover, manufacturers of TVR (and other artificial valves) must validate the design and durability of their devices before releasing them to the market. Despite its importance, there exists no realistic regulatory TVR testing machine. To address these needs, we will develop a platform to be used for two objectives: 1. As a predictive tool for planning clinical interventions: The tool will have the capability testing of effects of TVR intervention scenarios for correcting valvular diseases on the body of each patient body in a patient-specific manner. 2. As a regulatory medical-device testing machine: This machine can serve testing needs of medical-device companies by making it possible to perform many important in vivo evaluation routines in vitro and will significantly reduce the need for animal studies and human trials so it can significantly speed up the device approval process and reduce the time-to-market and cost-to-market for new devices.